Please login to the form below

Not currently logged in
Email:
Password:

vemurafenib

This page shows the latest vemurafenib news and features for those working in and with pharma, biotech and healthcare.

Roche gets FDA OKs for Alecensa and Zelboraf

Roche gets FDA OKs for Alecensa and Zelboraf

The US FDA has approved BRAF inhibitor Zelboraf (vemurafenib) for patients with ECD whose cancerous cells carry the BRAF V600 mutation, a group which accounts for just over half the 600

Latest news

More from news
Approximately 4 fully matching, plus 61 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    During this time, he was clinical lead for the development of Zelboraf (vemurafenib), which was co-developed by Roche and is predicted to reach peak-year sales of $1bn to

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics